Pulmonary hypertension in ROS1+ patients on TKIs

Two independent studies found ROS1+ lung cancer patients are more likely to develop blood clots than patients who have other lung cancers. Pulmonary embolisms are not uncommon in the ROS1ders, and these types of blood clots can eventually result in pulmonary hypertension (because it increases pressure on the heart). The appearance of a new blood … Continue reading Pulmonary hypertension in ROS1+ patients on TKIs

ROS1derings Winter 2020 (The ROS1ders newsletter)

Welcome to the Winter 2020 issue of ROS1derings, the newsletter of The ROS1ders! This issue contains info about on our patient-driven research, a fundraising update, a summary of current targeted therapies for ROS1+ cancers, and tips on parenting after a ROS1+ cancer diagnosis. Thanks to editors Joyce Hoelting and Jeff Wynne, and contributors Lisa Goldman, … Continue reading ROS1derings Winter 2020 (The ROS1ders newsletter)

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Dear Turning Point Therapeutics, Thank you so much for inviting me to speak to your employees about my personal ROS1 lung cancer story and the work of The ROS1ders. I truly appreciate your willingness to consider a patient perspective on ways to improve awareness of and access to biomarker testing and clinical trials for cancer patients. … Continue reading Thanks to ROS1ders’ Partner Turning Point Therapeutics

Ros1derings : August Edition

The second issue of our newsletter was released just over two weeks ago. For those who have missed it, you can grab it here : Ros1derings : August edition Contents include: A feature about Luna Okada, a 6.5 year ROS1der Some numbers about Xalkori use Fundraising updates Tips for traveling with stage 4 cancer An … Continue reading Ros1derings : August Edition

ROS1 abstracts at #WCLC19

Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10.  While the times and locations of sessions may change, the numbers and names will not.  ES14 – What First Line in Oncogene Addicted NSCLC 15:15 – 16:45 … Continue reading ROS1 abstracts at #WCLC19

The ROS1ders Interview Dr. Ross Camidge (16-May-2019)

On May 16, 2019, ROS1der co-founder Janet Freeman-Daily interviewed ROS1 expert D Ross Camidge, MD, PhD, Director of Thoracic Oncology and the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado in a Zoom Webinar. We discussed questions that have arisen among experienced patients in The ROS1ders regarding diagnosis, treatment, and research … Continue reading The ROS1ders Interview Dr. Ross Camidge (16-May-2019)